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Abstract
Background:  Numerous studies have implicated spinal extracellular signal-regulated kinases
(ERKs) as mediators of nociceptive plasticity. These studies have utilized pharmacological inhibition
of MEK to demonstrate a role for ERK signaling in pain, but this approach cannot distinguish
between effects of ERK in neuronal and non-neuronal cells. The present studies were undertaken
to test the specific role of neuronal ERK in formalin-induced inflammatory pain. Dominant negative
MEK (DN MEK) mutant mice in which MEK function is suppressed exclusively in neurons were
tested in the formalin model of inflammatory pain.
Results:  Formalin-induced second phase spontaneous pain behaviors as well as thermal
hyperalgesia measured 1 – 3 hours post-formalin were significantly reduced in the DN MEK mice
when compared to their wild type littermate controls. In addition, spinal ERK phosphorylation
following formalin injection was significantly reduced in the DN MEK mice. This was not due to a
reduction of the number of unmyelinated fibers in the periphery, since these were almost double
the number observed in wild type controls. Further examination of the effects of suppression of
MEK function on a downstream target of ERK phosphorylation, the A-type potassium channel,
showed that the ERK-dependent modulation of the A-type currents is significantly reduced in
neurons from DN MEK mice compared to littermate wild type controls.
Conclusion:  Our results demonstrate that the neuronal MEK-ERK pathway is indeed an
important intracellular cascade that is associated with formalin-induced inflammatory pain and
thermal hyperalgesia.
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Background
Extracellular signal-regulated kinases (ERKs) belong to a
cascade that is part of a phosphorelay system composed of
three sequentially activated kinases regulated by phos-
phorylation. Initiation of this cascade occurs via multiple
mechanisms which ultimately activate raf kinases. Acti-
vated raf phosphorylates MEK which phosphorylates
ERK1 and ERK2 on tyrosine and threonine residues. Extra-
cellular signal-regulated kinases are involved in the regu-
lation of meiosis and mitosis, and in differentiated cells,
ERKs integrate a wide variety of postmitotic functions [1-
3]. Within the past decade, numerous studies in rodents
have elucidated the role of ERKs in nociceptive plasticity.
ERK activation is activity-dependent, and occurs following
noxious stimulation [4,5]. The role of ERK in nociceptive
plasticity has been extensively studied in the spinal cord
and dorsal root ganglia, two important sites of nociceptive
sensitization [6-9]. In addition to different types of nox-
ious stimuli, high intensity electrical stimulation of C-fib-
ers also activates ERK in the spinal cord dorsal horn,
suggesting that C-fiber recruitment is crucial for release of
transmitters that activate ERK centrally in the spinal cord
[6,10].
ERK is expressed in neuronal as well as non-neuronal cells
[11] and the above mentioned studies have shown that
ERK activation occurs in both neuronal and glial cells of
the spinal cord. A recent study showed that ERK is sequen-
tially activated first in spinal neurons, then in microglia,
and then in astrocytes during the development of neuro-
pathic pain [12]. Activated microglia and astrocytes in the
spinal cord play a pivotal role in mediating enhanced pain
states. Noxious stimulation, such as occurs with a subcu-
taneous formalin injection in the paw, is associated with
glial cell activation [13,14]. Inhibitors of microglial acti-
vation can reduce persistent pain states [15]. It is thought
that glial cells may enhance pain states by releasing pro-
inflammatory cytokines and other substances that facili-
tate pain transmission [16]. Because ERK has been shown
to promote glial activation [17], it is possible that activa-
tion of ERK may lead to increased activity of spinal glial
cells in persistent pain states. Taken together with previ-
ous studies showing that ERK is strongly activated in dor-
sal horn neurons in response to noxious stimuli, and ERK
activation in dorsal horn neurons leads to alterations in
K+ channel function and enhanced excitability of these
cells [18,19], these data suggest that both neuronal and
glial cells may contribute to enhanced pain transmission
via ERK activation.
To study the importance of ERKs in nociception, most
studies mentioned above have utilized intrathecal phar-
macological inhibition of MEK using either PD 98059 or
U0126, which may inhibit MEK function in both neuro-
nal and non-neuronal cells. In addition to inhibiting ERK
activation in multiple cell types, high doses of PD98059
have direct inhibitory effects on Cam Kinase II [20] and
cyclooxygenase II [21]. U0126 used at higher doses, and
particularly with continuous perfusions, may lead to
motor effects [22] which may result in misinterpretation
of withdrawal responses. To address the above concerns,
and to evaluate the specific contribution of neuronal ERK
activation to pain behavior, we aimed to test whether
selective suppression of neuronal MEK activity can
decrease nociceptive plasticity using the formalin model.
We tested mutant mice that express dominant negative
MEK, whose expression was driven by the pan-neuronal
and neuron-specific Talpha1 alpha-tubulin promoter,
such that the dominant negative MEK protein is expressed
only in neurons. Our findings suggest that the neuronal
MEK-ERK cascade is required for inflammatory pain plas-
ticity.
Results
Reduced second phase of formalin test in the DN MEK 
mice
The formalin model is frequently used in the study of
inflammatory pain states in rodents. Injection of 2 % for-
malin subcutaneously in the hind paw of mice results in a
typical biphasic nociceptive response [23]. The first phase,
which usually lasts less than 5 minutes, occurs a few sec-
onds after formalin injection and is characterized by
intense spontaneous licking or lifting of the injected paw.
This phase is due to acute stimulation of nociceptors. The
second phase is characterized by licking and lifting of the
injected paw beginning at about 15–20 minutes after for-
malin injection and lasting until approximately 40–60
minutes after formalin. This second phase of nociception
is thought to involve central sensitization of dorsal horn
neurons as well as peripheral sensitization associated with
the inflammation [24]. We previously showed that in
mice, there is a reduced second phase of licking/lifting
behavior following attenuation of ERK activity by intrath-
ecal injection of the MEK inhibitor, PD 98059 [7]. In the
present study, we investigated the effects of reduced neu-
ronal MEK function in the DN MEK mice in the formalin
test. We performed experiments in male and female mice
since the MEK-ERK signaling pathway is a more dominant
component of inflammatory hyperalgesia in females
[25,26]. We find a significant gender difference in the
response to formalin; the female mice of both groups have
more significant spontaneous nociceptive behavior than
the male mice (p < 0.001, ANOVA). The first phase was
not altered in either the male or female DN MEK mice
when compared to their wild type littermates. However,
there was a significant reduction of the ascending part of
the second phase of the formalin test in both male and
female DN MEK mice (Fig 1). Thus, the neuronal MEK-
ERK cascade is important for the development of the sec-Molecular Pain 2006, 2:2 http://www.molecularpain.com/content/2/1/2
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ond phase of formalin-induced inflammatory nocicep-
tion.
Decreased thermal hyperalgesia in the DN MEK mice
We next investigated whether thermal hyperalgesia 1 to 3
hr after 2% formalin injection was altered in the DN MEK
mice. Baseline withdrawal latencies to radiant heat deter-
mined before formalin injection were similar in wild type
and DN MEK mice (Fig 2a). Female mice of both groups
(wild type and DN MEK) express more thermal hyperalge-
sia compared to the male mice (P < 0.001). Both the wild
type and DN MEK mice of both genders exhibited signifi-
cant ipsilateral thermal hyperalgesia (Fig 2b); however,
there is significantly less thermal hyperalgesia in the DN
MEK mice measured 1–3 hours after formalin injection
(Fig 2b) compared to their wild type littermates. These
results show that the DN MEK mice have reduced inflam-
matory thermal hyperalgesia. The thermal thresholds of
the contralateral uninjected paws were not significantly
different from their baselines in both male and female
mice (data not shown).
Decreased thermal hyperalgesia following intrathecal 
U0126
Following the observation that the DN MEK mice had less
thermal hyperalgesia following formalin injection, we
sought to determine whether the MEK inhibitor, U0126,
injected intrathecally would reduce thermal hyperalgesia
in wild type mice. A single intrathecal injection of U0126
(2 nmols, [22]) did not affect basal thermal thresholds
(Fig 3a); however, this treatment significantly decreased
thermal hyperalgesia 1 hour following formalin injection
in the U0126 treated mice compared to their vehicle con-
trols (Fig 3b).
Reduced ERK activation after formalin in DN MEK mice
We next investigated whether the reduced inflammatory
nociception was associated with reduced ERK activation
in the DN MEK mice. Extracellular signal-regulated
kinases have a central role in nociceptive sensitization in
the spinal cord; we therefore examined activation of ERK
at this site in either wild type or DN MEK mice following
formalin injection. Although basal phosphorylated ERK is
minimal in mouse spinal cords without noxious stimuli,
we investigated whether expression of the DN MEK trans-
gene would alter basal ERK activation in the DN MEK
mice. Levels of phosphorylated ERK in the lumbar spinal
cords of naïve mice were determined by immunoblotting
using a phospho-ERK-selective primary antibody. The
phospho-ERK bands were quantified and normalized to
total ERK immunoblotted from the same samples using
an anti-total ERK1/2 antibody. There was no significant
difference in the amount of basal phospho-ERK1 or phos-
pho-ERK2 between the wild type and DN MEK mice spi-
nal cords in either male or female mice (Fig 4a, 4b and
4c). We next investigated whether the DN MEK mice had
reduced activation of ERK following formalin injection.
We showed previously that injection of 2% – 5% formalin
Reduced second phase of formalin-induced nociceptive behavior in DN MEK mice Figure 1
Reduced second phase of formalin-induced nociceptive behavior in DN MEK mice. Time course of nociceptive behavior fol-
lowing 2 % formalin injection in the hind paws of either male (A) or female (B) wild type or DN MEK littermate mice. n = 12–
14 (male mice) per group, and 8–10 (female mice) per group. For this and the following graphs, data are presented as mean ± 
S.E.M. **p < 0.01, ***p < 0.001.Molecular Pain 2006, 2:2 http://www.molecularpain.com/content/2/1/2
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subcutaneously into the mouse hind paw induces a time-
dependent activation of ERK in the lumbar spinal cord [7]
which peaks at 3 minutes, remains sustained for up to 25
minutes and diminishes by 60 minutes. In the current
experiment, mice were killed 15 minutes after 2 % forma-
lin injection in the right hind paw. In the wild type mice,
blots of tissue taken from the side of the spinal cord ipsi-
lateral to the formalin injection showed significant stimu-
lation of both ERK1 and ERK2 when compared to the
contralateral side (Fig 5a and 5b), whereas ERK activation
in the spinal cords from the DN MEK mice was not signif-
icantly different from their contralateral sides. Further-
more, ipsilateral ERK2 activation was significantly lower
in the DN MEK mice than ipsilateral ERK2 activation in
the wild type mice. Taken together, these results indicate
that DN MEK mice have reduced formalin-induced
inflammatory pain as well as reduced formalin-induced
ERK activation in the spinal cord.
Unmyelinated fiber counts in cross sections of the sciatic 
nerve
ERKs also play an important role in development [2].
Because recruitment of C-fibers is necessary for spinal ERK
activation [6,10], we asked whether the reduction of spi-
nal neuronal ERK activation might be due to a reduction
in the number of peripheral unmyelinated fibers in the
DN MEK mice. Electron microscopy of sciatic nerve sec-
tions of wild type or DN MEK mice revealed that the DN
MEK mice had approximately twice the number of unmy-
elinated fibers as those counted in the wild type mice (Fig
6a, 6b, and 6c). Therefore, the reduction in spinal ERK
activation in the DN MEK mice is not due to reduced
number of unmyelinated peripheral fibers.
Decreased ERK-mediated modulation of A-type potassium 
currents in DN MEK mice
To further investigate whether there is a functional deficit
of the MEK-ERK cascade specifically in spinal cord neu-
rons of the DN MEK mice, we asked whether ERK regula-
tion of a downstream target, the transient A-type
potassium channel, is altered in these mice. ERK is known
to phosphorylate Kv4.2, an A-type potassium channel
subunit [27], and we have previously shown that MEK
inhibitors (U0126 or PD 98059) enhance A-type potas-
sium currents in dorsal horn neurons of the spinal cord
[19]. Dorsal horn cultures were prepared from either wild
type or DN MEK mice, and the effect of bath application
of 20 µM PD 98059 was examined. Neurons from the DN
MEK mice were significantly less sensitive to modulation
by the MEK inhibitor PD 98059 (Fig 7). These results con-
firm a reduced function of the MEK-ERK cascade in dorsal
horn neurons from the DN MEK mice.
Discussion
The present study reports several important findings
regarding the role of the neuronal MEK-ERK cascade in
nociception. The DN MEK mutant mice present a func-
tional reduction of the activity of neuronal MEK, the
kinase that selectively activates ERK 1 and ERK 2 [28]. The
DN MEK mice have a reduced second phase of licking
behavior following injection of 2% formalin in the hind
paw compared to the responses of their wild type litterma-
tes. These data are in a sense similar to our previous phar-
macological data where the intrathecally applied MEK
inhibitor PD 98059, selectively reduced the second phase
of licking behavior in mice [7]. However, the pattern of
the second phase reduction is different between the phar-
macological [6,7] and genetic suppression of neuronal
ERK activation. PD 98059 provided a much stronger sup-
pression of both the ascending and descending segments
of the formalin second phase behavior. The current data
shows a clear suppression, in both male and female mice,
only during the ascending part of the second phase, sug-
gesting that neuronal MEK-ERK cascade contributes to the
Reduced thermal hyperlagesia in DN MEK mice Figure 2
Reduced thermal hyperlagesia in DN MEK mice. A, Baseline 
thermal thresholds of male and female wild type and DN 
MEK mice. B, Thermal thresholds taken 1 to 3 hours follow-
ing injection of 2 % formalin, expressed as % of baseline val-
ues (shown as 100%, dashed line). n = 11–16 mice per group 
(male mice), and 12–15 mice per group (female mice). *p < 
0.05, ***p < 0.001, significant differences from baseline 
thresholds. #p < 0.05, significant differences between wild 
type and DN MEK mice.Molecular Pain 2006, 2:2 http://www.molecularpain.com/content/2/1/2
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development of the second phase spontaneous licking
behavior. Perhaps the larger suppression induced by
intrathecally applied MEK inhibitors is due to inhibition
of both neuronal and non-neuronal ERK activation.
Indeed it has been shown recently using a neuropathic
model that ERK is sequentially activated first in neurons,
followed by microglia, and later in astrocytes [12], and
taken together with our present data, we suggest that neu-
ronal ERK contributes to development of central sensitiza-
tion, which may later be maintained by non-neuronal
cells. Our data are also in agreement with a wealth of pre-
vious data reporting that MEK inhibitors reduce inflam-
matory pain using different pain models in rodents
[6,29,30]. In the current study, we do not rule out the con-
tribution of other nervous system structures to the
reduced behavioral effect in the DN MEK mice. However,
we do show that the contribution of the spinal cord to the
reduced behavioral effect is paramount since the activa-
tion of ERK1 and ERK2 is also decreased following forma-
lin injection in the DN MEK mice relative to wild type
littermates, and the behavioral and biochemical inhibi-
tion can be mimicked by intrathecal administration of
MEK inhibitors.
A recent paper reported decreased basal ERK activity in the
hippocampi of the DN MEK mice [31]. In the current
studies, we do not observe suppressed basal ERK activa-
tion in the spinal cords of the DN MEK mice. Basal ERK
activation is minimal in the spinal cord and spinal ERK
activation is activity-dependent and has been shown to
occur upon noxious or electrical stimulation of the
peripheral nerves [5-7]. It is unlikely that the decrease in
basal hippocampal ERK activity could produce decreased
nociception in the DN MEK mice. Shalin et al. (2004),
showed that despite the deficits in contextual fear-condi-
tioning in the DN MEK mice, these mice did not have sen-
sory deficits but rather comparable activity and anxiety
levels as that of the wild type mice. We show further in our
study, that there are no differences in basal thermal
thresholds.
Injection of 2% formalin in mice produced thermal
hyperalgesia (measured 1–3 hours after formalin injec-
tion), and more so in female mice than in the male litter-
mates. Ipsilateral thermal hyperalgesia was significantly
reduced in both the female and male DN MEK mice when
compared to littermate wild types. Parallel to these data, a
single intrathecal injection of U0126 reduced thermal
hyperalgesia induced by 2 % formalin in wild type mice.
Reduction of thermal hyperalgesia in the DN MEK mice is
possibly due to decreased central sensitization since we
showed clearly that spinal ERK activation following for-
malin injection was decreased in these mice. Possible
reduction of upstream activation of ERKs by glutamate
through either NMDA receptors [6], group I metabotropic
glutamate receptors [7,32] and/or neurotrophins such as
BDNF [33-35] could decrease central sensitization proc-
esses leading to reduced thermal hyperalgesia. Although
we do not rule out possible contributions of peripheral
activation of ERK through activation of TRPV1 [6,36-40],
this possibility seems unlikely because of the increased
number of unmyelinated fibers in the DN MEK mice.
However, future experiments will determine whether
TRPV1 channels and/or their functions are altered in the
DN MEK mice.
In this study we examined cross sections of the sciatic
nerves of the DN MEK mice in order to determine whether
reduced ERK activation following formalin injection was
Intrathecal injection of the MEK inhibitor, U0126, reduces  thermal hyperalgesia in wild type mice Figure 3
Intrathecal injection of the MEK inhibitor, U0126, reduces 
thermal hyperalgesia in wild type mice. A) Effect of intrathe-
cal injection of vehicle (7.5 % DMSO in PBS, pH 7.4) or 
U0126 (2 nmols) on thermal thresholds in mice. B) Effect of 
intrathecal pretreatment of either vehicle or U0126 (2 
nmols) 15 min prior to injection of 5 % formalin in the hind 
paw on thermal thresholds recorded 1 hr after formalin 
injection. n = 10 per group. *p < 0.05.Molecular Pain 2006, 2:2 http://www.molecularpain.com/content/2/1/2
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due to reduced number of unmyelinated peripheral fibers.
We were surprised to observe more unmyelinated fibers in
the sciatic nerves of the DN MEK mice, particularly given
that these mice showed no change in baseline thermal
sensitivity. However, similar unexpected findings have
been reported in the literature. For example, mice overex-
pressing glial cell line-derived neurotrophic factor or
nerve growth factor possess increased numbers of unmy-
elinated fibers, yet they do not display hyperalgesia [41].
The increased number of unmyelinated fibers in the DN
MEK mice could be a result of reduced ERK activity during
development. The MEK-ERK cascade has gained much
attention recently regarding the role of these kinases in
promoting neuronal cell death. Death of cerebellar gran-
ule neurons (CGN) cultured in low potassium concentra-
tions is accompanied by persistent ERK activation [42].
Inhibition of persistent activation of ERK with either MEK
inhibitors, or with overexpression of dominant negative
MEK in the cultures, resulted in a decrease in cell death of
the CGN [42,43]. Our present data from the DN MEK
mice are the first in vivo data that support a novel and
important role of the MEK-ERK cascade promoting neuro-
nal survival in the whole animal. Future experiments will
be designed to characterize this role in mice and especially
how the presence of the DN MEK affects the development
of primary afferent nerve fibers and their receptors in
nociception.
The current studies further show that ERK-mediated mod-
ulation of A-type potassium channels is impaired in spi-
nal dorsal horn neurons from DN MEK mice. ERKs are
known to directly phosphorylate Kv4.2, a K+ channel
alpha subunit that generates A-type potassium currents
[27]. Reduced ERK modulation of A-type potassium chan-
nels may contribute to decreased central sensitization of
spinal neurons leading to decreased pain after inflamma-
tion.
Conclusion
We show here, using transgenic mice with reduced neuro-
nal ERK activity, that neuronal ERK plays a key role in the
development of inflammatory nociceptive behavior, and
contributes to the processing of thermal hyperalgesia. Fur-
thermore, our results suggest that A-type potassium chan-
nels may be possible downstream targets of ERKs in the
regulation of inflammatory nociception.
Materials and methods
Tα1 DN-MEK transgenic mice generation
The generation of the DN MEK mice has been previously
described [31]. Briefly, a 1.1 kb Tα1 α-tubulin promoter
element that confers pan- neuronal and neuronal-specific
expression of the transgene [44,45] was used to drive the
expression of an HA-tagged K97M dominant negative
form of MEK [31,46]. The transgenic mice were estab-
lished in a C3H background strain, and back-crossed sev-
eral generations with C57 Bl/6 mice. For genotyping, tail
DNA was extracted following standard procedures and
used for PCR analysis. The primers used to amplify the
436 bp HA-DN MEK transgene were sense 5'-CCC ATA
CGA TGT TCC AGA TTA CGC-3' and antisense 5'-CGC
ACC ATA GAA GCC CAC GAT G-3' (Sigma -Genosys).
Basal phosphorylation of ERK is similar in the wild type and  DN MEK mice spinal cords Figure 4
Basal phosphorylation of ERK is similar in the wild type and 
DN MEK mice spinal cords. A, Representative immunoblot 
of mouse spinal cord homogenates using a phospho-ERK1/2 
antibody (top) or a total ERK1/2 antibody (bottom). The 
arrows show the position of the 44 kDa ERK 1 and 42 kDa 
ERK 2 isoforms. Quantification of ERK activation in male (B) 
and female (C) mice. Phospho-ERK bands were densitized 
and normalized to total ERK from the same samples. n = 8–9 
(male mice), and 8–9 (female mice).Molecular Pain 2006, 2:2 http://www.molecularpain.com/content/2/1/2
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Animal behavioral nociceptive testing
All experiments were done in accordance with the Animal
Care and Use Committee of Washington University
School of Medicine. Mice were housed in 12 hr/12 hr
light/dark cycles and given food ad libitum. Mice weighing
20–25 g were used for experiments. All experiments were
done using littermate controls and were performed with
the experimenter blind to the genotype. The formalin test
was performed as described previously [7]. Mice were
habituated in a transparent Plexiglas test box (5 × 5 × 10
inches) before any injections for I hr. 10 µl of 2 % forma-
lin solution was injected subcutaneously into the right
hind paw, and the mouse returned to the test box imme-
diately. The total time spent in nociceptive behavior (lick-
ing and lifting of the injected paw) was recorded in blocks
of five minutes for one hour. In separate experiments,
mice were habituated in Plexiglas chambers for 2–3
hours, and baseline thermal thresholds recorded. 10 µl of
2 % formalin solution was injected subcutaneously into
the right hind paw, and the mice were returned to the
chambers. Thermal thresholds were measured 1 hr fol-
lowing injection of formalin, and recorded for up to 3
hours. Thermal thresholds were measured as the latency
(seconds) to withdraw or lick the paw in response to a
constant radiant heat source through the glass bottom of
a chamber to the plantar surface of the hind paw (IITC Life
Sciences, Woodland hills, CA) [47].
Drug application
For electrophysiological recordings, the MEK inhibitor
PD98059 (Sigma, St. Louis, MO) was dissolved in 100 %
DMSO and diluted to the final concentration (20 µM) in
HBSS (Invitrogen Life Technologies, Carlsbad, CA). PD
98059 was applied by perfusion continuously at approxi-
mately 2–3 ml/min. For behavioral experiments, U0126
(Biomol, Plymouth Meeting, PA) was first dissolved in
100 % DMSO and diluted with PBS, pH 7.4 to a final con-
centration of 2 nmols in 3 µl. U0126 or the final concen-
tration of vehicle (7.5 % DMSO in PBS, Ph 7.4) was
injected intrathecally (i.t.) in a volume of 3 µl by lumbar
puncture using a Hamilton syringe and a 30 gauge needle.
Sample preparation
Mice were sacrificed 15 minutes after hind paw formalin
injection (2 %). The spinal cords were isolated and lum-
bar sections from individual mice were stored at -80°C.
Lumbar spinal cord enlargements (L4-S1) where indi-
cated, were separated into ipsilateral and contralateral sec-
tions and each homogenized using a dounce
homogenizer in ice-cold homogenization buffer (50 mM
Tris HCl, pH 7.5; 50 mM NaCl; 10 mM EGTA; 5 mM
EDTA; 2 mM sodium pyrophosphate, 1 mM sodium
orthovanadate; paranitrophenylphosphate; 1 mM phe-
nylmethylsulfonyl fluoride, 20 µg/ml leupeptin and 4 µg/
ml aprotinin, Sigma-Aldrich, St. Louis, MO). Protein con-
centrations were determined by the DC assay kit (Bio-Rad
laboratories, Hercules, CA).
Immunoblotting for total and phospho-ERK
10 µg of total protein was electrophoresed in 10% SDS
polyacrylamide gels. Proteins were transferred onto pro-
tein sensitive nitrocellulose membranes and blocked in B-
TTBS (3% bovine serum albumin (BSA); 50 mM Tris-HCl
pH 7.5; 150 NaCl; 0.02 mM Na Orthovanadate; 0.05%
Tween 20; 0.01% Thimerosal, Sigma-Aldrich, St. Louis,
MO) for 1 hour at room temperature. All antibody appli-
cations were done in B-TTBS. An antiphospho-p44/42
ERK primary antibody that detects ERK phosphorylation
at both Thr202 and Tyr204 (1:1000 dilution in B-TTBS,
Reduced phospho-ERK in DN MEK mice spinal cords 15  minutes after 2 % formalin injection in the hind paw Figure 5
Reduced phospho-ERK in DN MEK mice spinal cords 15 
minutes after 2 % formalin injection in the hind paw. A, Rep-
resentative immunoblots of ipsilateral (ipsi) and contralateral 
(contra) mouse spinal cord homogenates from a wild type or 
a DN MEK mouse using a phospho-ERK 1/2 antibody (top) 
or a total ERK 1/2 antibody (bottom). B, Quantification of 
ERK1 and ERK2 bands. Phospho-ERK bands were densitized 
and normalized to total ERK bands and expressed as % 
change of phospho-ERK on the ipsilateral side compared to 
the contralateral side (100 %). ***p < 0.001, significant differ-
ences between ipsilateral phospho-ERK and contralateral 
phospho-ERK. #p < 0.05, significant differences in ipsilateral 
phospho-ERK between the wild type and DN MEK mice. n = 
12 (wild type) and 7 (DN MEK).Molecular Pain 2006, 2:2 http://www.molecularpain.com/content/2/1/2
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Cell Signaling Technology, Beverly, MA), and an Anti-
p44/42 ERK primary antibody (1:1000 dilution in 3%
BSA, Cell Signaling Technology, Beverly, MA) that detects
total p44/42 isoforms were used for immunoblotting
overnight at 4°C. The blots were washed and incubated in
HRP-conjugated secondary antibody for 1 hour at room
temperature. Blots were developed with enhanced chemi-
luminescence (ECL, Amersham, Arlington Heights, IL).
Densitometric quantification of immunopositive bands
for total or phospho-ERK 1/2 were performed using Scion
Image software.
Cell culture
All reagents for cell culture were purchased from Invitro-
gen Life Technologies, Carlsbad, CA, except where other-
wise mentioned. Primary cultures of spinal cord dorsal
horn were prepared from 3–7 day old mice using our pre-
vious protocol [19]. Briefly, the mice were killed by decap-
itation and a laminectomy performed to obtain the spinal
cord. The spinal cord superficial dorsal horn was isolated
and chopped into several strips which were incubated for
45 minutes at 37°C in Hank's balanced salt solution
(HBSS) containing papain (15 U/ml: Worthington Bio-
chemical, Lakewood, NJ). The strips were rinsed 3 times
with HBSS, and placed in culture medium containing
Neurobasal, 5% fetal calf serum, 5% heat-inactivated
horse serum, 100 U/ml penicillin, 100 µg/ml streptomy-
cin, 2 mM L-glutamax-1, 1% B-27 and 12 mM glucose
(SIGMA-ALDRICH, St. Louis, MO). The cells were dissoci-
ated by triturition with a fire-polished Pasteur pipette. The
cells were plated onto poly-D-lysine and collagen-coated
coverslips, and cultured for 1 to 2 days in humidified air
with 5% CO2 at 37°C.
Electrophysiological recording
Whole cell recordings were performed as described in our
previous work [19]. Briefly, whole cell recordings were
made by standard procedures at room temperature with
an EPC-10 amplifier and PULSE software (HEKA Ele-
ktronic, Lambrecht, Germany). Electrodes were pulled
from filamented borosilicate glass and fire polished to a
resistance of 3–6 MΩ. Most neurons had series resistance
around 6–10 MΩ (range, 5–18 MΩ), which was compen-
sated ≥65%. Input resistance was 1.00 ± 0.05 GΩ. Most
neurons had leak currents < 100pA (-80 mV) which were
not subtracted on-line. The bath solution (HBSS) con-
tained 500 nM TTX and 2 mM CoCl2 to block voltage
gated Na+ currents, Ca2+ currents and Ca2+ -activated K+
currents. The electrode solution contained (in mM): 140
KCl, 1 mgCl2, 0.5 CaCl2, 5 EGTA, 10 HEPES, 3 Na2ATP,
0.3 Na2GTP, pH adjusted to 7.4 with KOH. The mem-
brane voltage was held at -80 mV and potassium currents
were evoked by a command potential of +40 mV. The
transient A-type current was isolated by subtracting the
sustained current evoked by a step to +40 mV with a 150
ms prepulse to -10 mV [19].
Unmyelinated fiber counts in cross sections of the sciatic 
nerve
Mice were anesthetized with 50 mg/kg pentobarbital and
the skin on the dorsal thigh was cut open. The muscles
were separated with blunt dissection and the sciatic nerve
exposed. One centimeter of the nerve was removed and
immersed in a fixative (CAC) containing 2% paraformal-
dehyde, 2.5% gluteraldehyde, 0.1 M cacodylic acid pH 7.2
for 1 hour. After multiple rinses in CAC, samples were
then fixed in 1% osmium tetroxide in CAC for an addi-
tional hour and then stained enblock in 1% uranyl acetate
in h20 for 1 hour. Samples were then dehydrated through
a series of ETOH, propylene oxide and then infiltrated and
embedded in monomeric Embed 812 (Electron Micros-
copy Sciences). Blocks were sectioned with an RMC MTXL
ultramicrotome at approximately 75–80 nm with a Dia-
tome diamond knife, stained with Pb citrate, Uranyl ace-
tate. Grids were viewed on a Hitachi H7500 transmission
Representative electron micrographs of cross sections of the  sciatic nerves of A) wild type and B) DN MEK mice Figure 6
Representative electron micrographs of cross sections of the 
sciatic nerves of A) wild type and B) DN MEK mice. Small 
diameter unmyelinated fibers (UM) are often present as 
encapsulated bunches of fibers in between the myelinated fib-
ers. Thick arrowheads point to the Schwann cells of the large 
diameter myelinated fibers (LM). Small arrows point to the 
Schwann cells of the small diameter myelinated fibers (SM). S 
represents the Schwann cell of the unmyelinated fibers. C) 
Bar graph showing the mean number of unmyelinated fibers 
per 100 µm2. ***P < 0.001, n = 363 and 377 images from 2 
wild type and 2 DN MEK mice sciatic nerves respectively.Molecular Pain 2006, 2:2 http://www.molecularpain.com/content/2/1/2
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electron microscope with Advanced Microscopy Tech-
niques (AMT) digital image capturing software and
Hamamatsu digital camera. A total of 363 and 377 micro-
graphs, from 2 wild type and 2 DN MEK mice respectively,
were captured diagonally across the sciatic nerve by a per-
son blind to the genotypes, and the images saved. The
number of unmyelinated fibers was counted and the
mean number of unmyelinated fibers was expressed per
100  µm2.
Statistical analysis
Behavioral and immunoblot data were analyzed using
one way or two way ANOVA on the Prism statistical pro-
gram, followed by Bonferroni's or Newman-Keuls post
hoc tests. Data from electrophysiology was evaluated off-
line using Pulsefit software (HEKA Elektronic, Lambrecht,
Germany) and Origin (Microcal Software, Northampton,
MA) and Paired Student's t-test was used to compare drug
effects from controls. Unpaired Student's t-test was used
to compare the number of unmyelinated fibers between
the DN MEK and wild type mice.
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